Ricard Solà
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ricard Solà has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Susanna Coll
Servei Digestiu, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
3 shared publications Silvia Montoliu
Liver Section, Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain
2 shared publicationsA. Soler
Department of Clinical Pharmacology, Hospital Universitari Germans Trias i Pujol, Badalona
1 shared publication- Antoni Mas
Liver Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain
1 shared publication Belén Ballesté
Liver Section, Department of Gastroenterology, Hospital del Mar, Barcelona, Spain
1 shared publicationBonaventura Clotet
HIV Clinical Unit/Fundació de la Lluita contra la SIDA/Internal Medicine Service, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain
1 shared publication
Latest Publications
- Open Access
- 15 July 2011
- Published by Springer Nature in BMC Gastroenterology
- Vol. 11 (1) , 80
Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series
Background: Acute liver injury (ALI) induced by paracetamol overdose is a well known cause of emergency hospital admission and death. However, there is debate regarding the risk of ALI after therapeutic dosages of the drug. The aim is to describe the characteristics of patients admitted to hospital with jaundice who had previous exposure to therapeutic doses of paracetamol. An assessment of the causality role of paracetamol was performed in each case. Methods: Based on the evaluation of prospectively gathered cases of ALI with detailed clinical information, thirty-two cases of ALI in non-alcoholic patients exposed to therapeutic doses of paracetamol were identified. Two authors assessed all drug exposures by using the CIOMS/RUCAM scale. Each case was classified into one of five categories based on the causality score for paracetamol. Results: In four cases the role of paracetamol was judged to be unrelated, in two unlikely, and these were excluded from evaluation. In seven of the remaining 26 cases, the RUCAM score associated with paracetamol was higher than that associated with other concomitant medications. The estimated incidence of ALI related to the use of paracetamol in therapeutic dosages was 0.4 per million inhabitants older than 15 years of age and per year (99%CI, 0.2-0.8) and of 10 per million paracetamol users-year (95% CI 4.3-19.4). Conclusions: Our results indicate that paracetamol in therapeutic dosages may be considered in the causality assessment in non-alcoholic patients with liver injury, even if the estimated incidence of ALI related to paracetamol appears to be low.
- 15 July 2011
- Published by Springer Nature in BMC Gastroenterology
- Vol. 11 (1) , 80
Open AccessParacetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series
Background: Acute liver injury (ALI) induced by paracetamol overdose is a well known cause of emergency hospital admission and death. However, there is debate regarding the risk of ALI after therapeutic dosages of the drug. The aim is to describe the characteristics of patients admitted to hospital with jaundice who had previous exposure to therapeutic doses of paracetamol. An assessment of the causality role of paracetamol was performed in each case. Methods: Based on the evaluation of prospectively gathered cases of ALI with detailed clinical information, thirty-two cases of ALI in non-alcoholic patients exposed to therapeutic doses of paracetamol were identified. Two authors assessed all drug exposures by using the CIOMS/RUCAM scale. Each case was classified into one of five categories based on the causality score for paracetamol. Results: In four cases the role of paracetamol was judged to be unrelated, in two unlikely, and these were excluded from evaluation. In seven of the remaining 26 cases, the RUCAM score associated with paracetamol was higher than that associated with other concomitant medications. The estimated incidence of ALI related to the use of paracetamol in therapeutic dosages was 0.4 per million inhabitants older than 15 years of age and per year (99%CI, 0.2-0.8) and of 10 per million paracetamol users-year (95% CI 4.3-19.4). Conclusions: Our results indicate that paracetamol in therapeutic dosages may be considered in the causality assessment in non-alcoholic patients with liver injury, even if the estimated incidence of ALI related to paracetamol appears to be low.
- Open Access
- 6 November 2007
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 27 (3) , 257-265
De novo depression and anxiety disorders and influence on adherence during peginterferon‐alpha‐2a and ribavirin treatment in patients with hepatitis C
Summary: Background Depression and anxiety have been associated with interferon treatment and low treatment adherence.Aim To study the incidence and associated risk factors of depressive and anxiety disorders during pegylated interferon plus ribavirin and treatment adherence in a prospective cohort of 176 patients with chronic hepatitis C patients.Methods Patients were interviewed at baseline using the Structured Clinical Interview for DSM‐IV Mental Disorders and the Patient Health Questionnaire and the Hospital Anxiety and Depression Scale were completed. Both questionnaires were completed also after 4, 12 and 24 weeks of treatment.Results De novo depressive and/or anxiety disorders were diagnosed in 53 (36%) patients, in whom antidepressants and/or anxiolytics were administered. Higher baseline depression‐subscale score (OR = 27.8, 95% CI = 2.82–333), primary education level (OR = 3.1, 95% CI = 1.40–7.03) and being an immigrant (OR = 3.2, 95% CI = 1.12–9.47) were predictors of psychiatric disorders during anti‐viral therapy. The percentage of patients with good adherence was lower in those with depression and/or anxiety (79% vs. 90%, P < 0.04). Only one patient (1%) discontinued treatment because of a major depressive episode. Depression and/or anxiety disorders had no effect on attainment of sustained virological response.Conclusion Early detection and treatment of depressive and anxiety disorders favours good adherence to anti‐viral treatment in hepatitis C.
- 6 November 2007
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 27 (3) , 257-265
Open AccessDe novo depression and anxiety disorders and influence on adherence during peginterferon‐alpha‐2a and ribavirin treatment in patients with hepatitis C
Summary: Background Depression and anxiety have been associated with interferon treatment and low treatment adherence.Aim To study the incidence and associated risk factors of depressive and anxiety disorders during pegylated interferon plus ribavirin and treatment adherence in a prospective cohort of 176 patients with chronic hepatitis C patients.Methods Patients were interviewed at baseline using the Structured Clinical Interview for DSM‐IV Mental Disorders and the Patient Health Questionnaire and the Hospital Anxiety and Depression Scale were completed. Both questionnaires were completed also after 4, 12 and 24 weeks of treatment.Results De novo depressive and/or anxiety disorders were diagnosed in 53 (36%) patients, in whom antidepressants and/or anxiolytics were administered. Higher baseline depression‐subscale score (OR = 27.8, 95% CI = 2.82–333), primary education level (OR = 3.1, 95% CI = 1.40–7.03) and being an immigrant (OR = 3.2, 95% CI = 1.12–9.47) were predictors of psychiatric disorders during anti‐viral therapy. The percentage of patients with good adherence was lower in those with depression and/or anxiety (79% vs. 90%, P < 0.04). Only one patient (1%) discontinued treatment because of a major depressive episode. Depression and/or anxiety disorders had no effect on attainment of sustained virological response.Conclusion Early detection and treatment of depressive and anxiety disorders favours good adherence to anti‐viral treatment in hepatitis C.
- 1 May 2006
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 22 (5) , 393-400
Poor Response to Hepatitis C Virus (HCV) Therapy in HIV- and HCV-Coinfected Patients Is Not Due to Lower Adherence to Treatment
The degree of adherence to anti-hepatitis C virus (HCV) therapy among HIV/HCV-coinfected patients is not known. A prospective cohort study was performed in two groups of patients: 79 HIV/HCV-coinfected patients (group 1) and 78-HCV-monoinfected patients (group 2). Patients were treated with interferon alpha-2a (3 million international units [MIU], three times per week) plus ribavirin (1000-1200 mg/day) for 48 weeks. Adherence to therapy was defined as having received +/-80% of both drug dosages for +/-80% of the expected duration of therapy. The degree of adherence to treatment was similar for patients with or without HIV coinfection (72.2 versus 80.8%). The overall sustained virological response (SVR) in patients with adherence to therapy was 41.7% as compared with only 8.1% (p = 0.0001) in patients without adherence. The difference in SVR rate according to adherence to treatment was also evident in patients of group 1 (29.8% versus 9.1%; p = 0.05) as well as in those of group 2 (52.4 versus 6.7%; p = 0.001). Adherence to anti-HCV therapy, which can be similar in mono- and coinfected patients, enhances the likelihood of achieving an increase in SVR rate. In addition to improved adherence, in coinfected patients more aggressive therapeutic strategies may be necessary to achieve SVR.
- 1 May 2006
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 22 (5) , 393-400
Poor Response to Hepatitis C Virus (HCV) Therapy in HIV- and HCV-Coinfected Patients Is Not Due to Lower Adherence to Treatment
The degree of adherence to anti-hepatitis C virus (HCV) therapy among HIV/HCV-coinfected patients is not known. A prospective cohort study was performed in two groups of patients: 79 HIV/HCV-coinfected patients (group 1) and 78-HCV-monoinfected patients (group 2). Patients were treated with interferon alpha-2a (3 million international units [MIU], three times per week) plus ribavirin (1000-1200 mg/day) for 48 weeks. Adherence to therapy was defined as having received +/-80% of both drug dosages for +/-80% of the expected duration of therapy. The degree of adherence to treatment was similar for patients with or without HIV coinfection (72.2 versus 80.8%). The overall sustained virological response (SVR) in patients with adherence to therapy was 41.7% as compared with only 8.1% (p = 0.0001) in patients without adherence. The difference in SVR rate according to adherence to treatment was also evident in patients of group 1 (29.8% versus 9.1%; p = 0.05) as well as in those of group 2 (52.4 versus 6.7%; p = 0.001). Adherence to anti-HCV therapy, which can be similar in mono- and coinfected patients, enhances the likelihood of achieving an increase in SVR rate. In addition to improved adherence, in coinfected patients more aggressive therapeutic strategies may be necessary to achieve SVR.
- 31 October 2005
- Published by Wiley in Liver International
- Vol. 26 (1) , 62-72
Probability of liver cancer and survival in HCV‐related or alcoholic‐decompensated cirrhosis. A study of 377 patients
Abstract: Background:Although chronic alcohol intake and chronic hepatitis C may progress to cirrhosis and hepatocellular carcinoma (HCC), few data are available about survival and probability of developing HCC in decompensated cirrhosis of both aetiologies.Methods:This study identified factors related with probability of developing HCC and survival in a cohort of 377 consecutive patients with decompensated HCV‐related cirrhosis (200 cases) or alcoholic cirrhosis (177 cases) without known HCC, hospitalized for their first hepatic decompensation, as well as to evaluate differences between both aetiologies. Patients were followed for a mean period of 39±2 months.Results:During follow‐up, 42 patients (11.1%) developed HCC (16.5% vs 5.1%) in groups HCV and alcohol, respectively; p=0.0008), and 131 patients (34.7%) died (42% vs 26.6% in groups HCV and alcohol, respectively; p=0.002). Age and HCV‐cirrhosis were independently related to HCC development, while baseline age and Child‐Turcotte‐Pugh score were independently correlated with survival.Conclusion:Survival in decompensated HCV‐related or alcoholic cirrhosis is influenced by age and baseline Child‐Turcotte‐Pugh score, without differences in cirrhosis aetiology. The risk of developing HCC is greater in HCV‐related cirrhosis than in alcoholic cirrhosis.
- 31 October 2005
- Published by Wiley in Liver International
- Vol. 26 (1) , 62-72
Probability of liver cancer and survival in HCV‐related or alcoholic‐decompensated cirrhosis. A study of 377 patients
Abstract: Background:Although chronic alcohol intake and chronic hepatitis C may progress to cirrhosis and hepatocellular carcinoma (HCC), few data are available about survival and probability of developing HCC in decompensated cirrhosis of both aetiologies.Methods:This study identified factors related with probability of developing HCC and survival in a cohort of 377 consecutive patients with decompensated HCV‐related cirrhosis (200 cases) or alcoholic cirrhosis (177 cases) without known HCC, hospitalized for their first hepatic decompensation, as well as to evaluate differences between both aetiologies. Patients were followed for a mean period of 39±2 months.Results:During follow‐up, 42 patients (11.1%) developed HCC (16.5% vs 5.1%) in groups HCV and alcohol, respectively; p=0.0008), and 131 patients (34.7%) died (42% vs 26.6% in groups HCV and alcohol, respectively; p=0.002). Age and HCV‐cirrhosis were independently related to HCC development, while baseline age and Child‐Turcotte‐Pugh score were independently correlated with survival.Conclusion:Survival in decompensated HCV‐related or alcoholic cirrhosis is influenced by age and baseline Child‐Turcotte‐Pugh score, without differences in cirrhosis aetiology. The risk of developing HCC is greater in HCV‐related cirrhosis than in alcoholic cirrhosis.
- 1 April 2002
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 14 (4) , 351-354
Why do bacteria reach ascitic fluid?
Spontaneous bacterial peritonitis (SBP) is the most common and serious infection that develops in cirrhotic patients. Translocation of bacteria from their intestinal origin, alterations in immune defence mechanisms and deficiencies in the ascitic fluid antimicrobial activity seem to represent the main steps in the pathogenesis of SBP in cirrhosis. Among the factors determining the development of bacterial translocation, intestinal bacterial overgrowth (mainly related to decreased intestinal motility) and changes in the intestinal barrier appear to play an outstanding role. In conclusion, greater understanding of the pathogenesis of SBP will allow better identification of patients at high risk of developing this complication and contribute to the search for new strategies for its prevention.
- 1 April 2002
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 14 (4) , 351-354
Why do bacteria reach ascitic fluid?
Spontaneous bacterial peritonitis (SBP) is the most common and serious infection that develops in cirrhotic patients. Translocation of bacteria from their intestinal origin, alterations in immune defence mechanisms and deficiencies in the ascitic fluid antimicrobial activity seem to represent the main steps in the pathogenesis of SBP in cirrhosis. Among the factors determining the development of bacterial translocation, intestinal bacterial overgrowth (mainly related to decreased intestinal motility) and changes in the intestinal barrier appear to play an outstanding role. In conclusion, greater understanding of the pathogenesis of SBP will allow better identification of patients at high risk of developing this complication and contribute to the search for new strategies for its prevention.
- 1 January 2002
- Published by Elsevier in Medicina Clinica
- Vol. 119 (3) , 90-95
Prevalencia de las hepatitis B y C en diversas comarcas de Cataluña: estudio transversal
- 1 January 2002
- Published by Elsevier in Medicina Clinica
- Vol. 119 (3) , 90-95
Prevalencia de las hepatitis B y C en diversas comarcas de Cataluña: estudio transversal